CAL02

About Eagle Pharmaceuticals

Eagle Pharmaceuticals is a NASDAQ-listed company (EGRX) headquartered in Woodcliff Lake, NJ, dedicated to developing innovative drugs that result in meaningful improvements in patients' lives. The company operates with a strategic focus on critical care and oncology, balancing a commercial-stage portfolio with a pipeline of novel product candidates. Eagle's mission is to bring brilliant science to life by serving patients, healthcare providers, and health systems, thereby creating value for all stakeholders.

About Combioxin

Combioxin is dedicated to revolutionizing the treatment of severe infections and immune dysfunction in intensive care. Its core technology uses proprietary engineered liposomes to capture and neutralize bacterial toxins, offering a novel mechanism against both Gram-positive and Gram-negative pathogens. The company has achieved significant regulatory milestones for CAL02, initiated a global Phase 2b study, and secured a worldwide out-licensing agreement with Eagle Pharmaceuticals, positioning it to address a critical unmet medical need with high mortality and cost.

Therapeutic Areas